ENTITY

SMARTSCORE: 3.2/5

Shanghai Henlius Biotech (2696 HK)

276

Analysis

Health Care • China

Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.

more

Refresh

Exchange Announcement • 25 Apr 2025 09:45

Inside Information Announcement - License Agreement With Alvogen Korea In Respect Of Hansizhuang

Exchange Announcement • 17 Apr 2025 09:35

Voluntary Announcement - First Patient Has Been Dosed In The Phase 2 Clinical Study Of Hlx22 (Recombinant Humanized Anti-Her2 Monoclonal Antibody Injection) In Combination With Trastuzumab Deruxtecan For The Treatment Of Locally Advanced Or Metastatic Breast Cancer In Mainland China

Exchange Announcement • 15 Apr 2025 08:48

Proxy Form For The Annual General Meeting To Be Held On Thursday, 8 May 2025 (Or Any Adjournment Thereof)

Exchange Announcement • 15 Apr 2025 08:46

Notice Of Annual General Meeting

Exchange Announcement • 15 Apr 2025 08:42

Annual General Meeting; Re-Appointment Of Auditors; Grant Of General Mandates To Issue Shares And Repurchase H Shares; Proposed Amendments To The Articles Of Association; Notices Of Agm

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.52.8

x